Inclusion Criteria:

1. Histologically confirmed TCC of the urothelial tract (bladder, renal pelvis, or
ureter)

2. Prior exposure to gemcitabine-platinum regimen as either adjuvant or palliative
chemotherapy.

3. Unidimensionally measurable disease outside prior radiotherapy ports

4. Age 18 years or older

5. ECOG performance status of 0~2

6. Life expectancy of at least 3 months

7. Adequate BM function (ANC >1,500/mm3 & Platelet >100,000/mm3)

8. Adequate hepatic function (Bilirubin no greater than 2 times upper limit of normal
(ULN) & AST or ALT no greater than 2.5 times ULN), and renal function (creatinine
<1.5 X times ULN)

9. No pre-existing clinically significant grade 2 or greater neuropathy

Exclusion Criteria:

1. Pregnant or lactating patients

2. Presence or history of CNS metastasis

3. Patients with prior RT to the axial skeleton within 4 weeks of chemotherapy start to
greater than 25% of bone marrow

4. Any preexisting medical condition of sufficient severity to prevent full compliance
with the study, including active infection, active cardiac symptoms